KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Operating Expenses (2016 - 2025)

Arbutus Biopharma's Operating Expenses history spans 13 years, with the latest figure at $9.2 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 59.66% year-over-year to $9.2 million; the TTM value through Sep 2025 reached $61.4 million, down 31.67%, while the annual FY2024 figure was $82.5 million, 14.29% down from the prior year.
  • Operating Expenses for Q3 2025 was $9.2 million at Arbutus Biopharma, down from $9.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $28.8 million in Q4 2022 and bottomed at $9.2 million in Q3 2025.
  • The 5-year median for Operating Expenses is $23.0 million (2023), against an average of $21.8 million.
  • The largest annual shift saw Operating Expenses skyrocketed 43.1% in 2021 before it tumbled 60.31% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $24.0 million in 2021, then rose by 20.02% to $28.8 million in 2022, then dropped by 20.53% to $22.9 million in 2023, then crashed by 32.26% to $15.5 million in 2024, then crashed by 40.75% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Operating Expenses are $9.2 million (Q3 2025), $9.3 million (Q2 2025), and $27.5 million (Q1 2025).